恒瑞医药(600276.SH)：泽美妥司他片获得药品注册批准

Core Viewpoint - Heng Rui Medicine (600276.SH) has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554 tablets, which is the first EZH2 inhibitor developed in China, aimed at adult patients with relapsed or refractory peripheral T-cell lymphoma who have previously undergone at least one line of systemic therapy [1] Company Summary - The company has developed SHR2554 tablets, marking a significant milestone as it is the first EZH2 inhibitor independently developed in China [1] - The approval is specifically for adult patients with relapsed or refractory peripheral T-cell lymphoma, indicating a targeted therapeutic application [1] Industry Summary - The approval of SHR2554 tablets highlights advancements in the oncology sector, particularly in the development of innovative treatments for complex hematological malignancies [1] - The introduction of the first EZH2 inhibitor in the Chinese market may enhance competition and innovation within the pharmaceutical industry, particularly in the field of cancer treatment [1]